← Leaderboards
Barbara Felber
Basic Sciences
$1,111,781
Attributed
$1,111,781
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $207.1K · FY2005–09$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$1,111,781 · 6
By mechanism
P51$1,111,781 · 6
Top collaborators
No co-investigators on record.
Most similar at Basic Sciences
Same institution · by research overlap
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusCytokineImmune ResponseMacacaVaccinesAdjuvantAntigensResponseDna VaccinesVaccinationMolecularRegimenInterleukin-12Expression VectorHiv VaccineProteinsElementsGene ExpressionViralIn VivoReportingEpitopesVaccine DevelopmentClinical Trials
Grant awards (68)
Nucleic acid-based vaccine for HIV and other indications$1,725,137
ZIA · FY2025 · CA · contact PI
Cytokine and immunotherapy in cancer and AIDS$1,725,137
ZIA · FY2025 · CA · contact PI
Conserved Element DNA Vaccine$383,363
ZIA · FY2025 · CA · contact PI
Examining IL-15 and IL-7 as an immunotherapy agent in cancer and AIDS$1,786,891
ZIA · FY2024 · CA · contact PI
Development testing of nucleic acid-based vaccine for HIV other indications$1,786,891
ZIA · FY2024 · CA · contact PI
Conserved Element DNA Vaccine$1,021,081
ZIA · FY2024 · CA · contact PI
COVID-19 vaccine in naive individuals and cancer patients$510,540
ZIA · FY2024 · CA · contact PI
Development testing of nucleic acid-based vaccine for HIV other indications$1,950,208
ZIA · FY2023 · CA · contact PI
Examining IL-15 and IL-7 as an immunotherapy agent in cancer and AIDS$1,121,375
ZIA · FY2023 · CA · contact PI
COVID-19 vaccine in naive individuals and cancer patients$851,991
ZIA · FY2023 · CA · contact PI
Conserved Element DNA Vaccine$681,593
ZIA · FY2023 · CA · contact PI
Development testing of nucleic acid-based vaccine for HIV other indications$845,848
ZIA · FY2022 · CA · contact PI
Examining IL-15 as an immunotherapy agent in cancer and AIDS$704,873
ZIA · FY2022 · CA · contact PI
COVID-19 vaccine in naive individuals and cancer patients$704,873
ZIA · FY2022 · CA · contact PI
Conserved Element DNA Vaccine$563,898
ZIA · FY2022 · CA · contact PI
Prevention of AIDS$1,300,391
ZIA · FY2021 · CA · contact PI
Conserved Element DNA Vaccine$1,300,391
ZIA · FY2021 · CA · contact PI
COVID-19 vaccine development research$650,195
ZIA · FY2021 · CA · contact PI
Prevention of AIDS$1,866,900
ZIA · FY2020 · CA · contact PI
Conserved Element DNA Vaccine$1,866,900
ZIA · FY2020 · CA · contact PI
COVID-19 vaccine development research$933,451
ZIA · FY2020 · CA · contact PI
Prevention of AIDS$2,251,746
ZIA · FY2019 · CA · contact PI
Conserved Element DNA Vaccine$2,251,746
ZIA · FY2019 · CA · contact PI
Prevention of AIDS$1,083,056
ZIA · FY2018 · CA · contact PI
Conserved Element DNA Vaccine$1,083,056
ZIA · FY2018 · CA · contact PI
Prevention of AIDS$1,593,708
ZIA · FY2017 · CA · contact PI
Immunotherapeutic Interventions of AIDS and Cancer$1,062,472
ZIA · FY2017 · CA · contact PI
Prevention of AIDS$1,872,396
ZIA · FY2016 · CA · contact PI
Posttranscriptional control of gene expression$468,099
ZIA · FY2016 · CA · contact PI
Prevention of AIDS$1,921,959
ZIA · FY2015 · CA · contact PI
Posttranscriptional control of gene expression$480,490
ZIA · FY2015 · CA · contact PI
Prevention of AIDS$2,053,144
ZIA · FY2014 · CA · contact PI
Posttranscriptional control of gene expression$513,285
ZIA · FY2014 · CA · contact PI
Prevention of AIDS$2,168,641
ZIA · FY2013 · CA · contact PI
Posttranscriptional control of gene expression$542,160
ZIA · FY2013 · CA · contact PI
Prevention of AIDS$1,862,956
ZIA · FY2012 · CA · contact PI
Posttranscriptional control of gene expression$465,740
ZIA · FY2012 · CA · contact PI
Prevention of AIDS$1,858,866
ZIA · FY2011 · CA · contact PI
Posttranscriptional control of gene expression$796,657
ZIA · FY2011 · CA · contact PI
Prevention of AIDS$1,791,918
ZIA · FY2010 · CA · contact PI
Posttranscriptional control of gene expression$767,965
ZIA · FY2010 · CA · contact PI
Prevention of AIDS$2,024,238
ZIA · FY2009 · CA · contact PI
Posttranscriptional control of gene expression$867,531
ZIA · FY2009 · CA · contact PI
PATHOGENICITY OF SIVMAC239 VARIANTS IN NEONATAL MACAQUES$109,904
P51 · FY2009 · RR · contact PI
Prevention of AIDS$2,417,438
Z01 · FY2008 · CA · contact PI
Posttranscriptional control of gene expression$1,036,045
Z01 · FY2008 · CA · contact PI
PATHOGENICITY OF SIVMAC239 VARIANTS IN NEONATAL MACAQUES$168,995
P51 · FY2008 · RR · contact PI
Prevention of AIDS$768,111
Z01 · FY2007 · CA · contact PI
Posttranscriptional control of gene expression$548,767
Z01 · FY2007 · CA · contact PI
PATHOGENICITY OF SIVMAC239 VARIANTS IN NEONATAL MACAQUES$181,569
P51 · FY2007 · RR · contact PI
PATHOGENICITY OF SIVMAC239 VARIANTS IN NEONATAL MACAQUES$156,653
P51 · FY2006 · RR · contact PI
Prevention of AIDS$0
Z01 · FY2006 · BC · contact PI
Posttranscriptional control of gene expression$0
Z01 · FY2006 · BC · contact PI
PATHOGENICITY OF SIVMAC239 VARIANTS IN NEONATAL MACAQUES$207,141
P51 · FY2005 · RR
Prevention of AIDS$0
Z01 · FY2005 · BC
Posttranscriptional control of gene expression$0
Z01 · FY2005 · BC
PATHOGENICITY OF SIVMAC239 VARIANTS IN NEONATAL MACAQUES$122,318
P51 · FY2004 · RR
Pathogenicity and immunogenicity of live attenuated SIV$0
Z01 · FY2004 · BC
Posttranscriptional control of gene expression$0
Z01 · FY2004 · BC
PATHOGENICITY OF REV INDEPENDENT SIVMAC239 VARIANTS IN NEONATAL MACAQUES$165,201
P51 · FY2003 · RR
Pathogenicity and Immunogenicity of Live Attenuated SIV$0
Z01 · FY2003 · BC
Posttranscriptional control of gene expression$0
Z01 · FY2003 · BC
Pathogenicity and immunogenicity of live attenuated SIV$0
Z01 · FY2002 · BC
Posttranscriptional control of gene expression$0
Z01 · FY2002 · BC
Pathogenicity and immunogenicity of live attenuated SIV$0
Z01 · FY2001 · BC
Posttranscriptional control of gene expression$0
Z01 · FY2001 · BC
PATHOGENICITY &IMMUNOGENICITY OF HIV &SIV STRAINS$0
Z01 · FY2000 · BC
MECHANISMS OF POSTTRANSCRIPTIONAL MRNA REGULATION$0
Z01 · FY2000 · BC